Search - tctmd.com

Displaying 1 - 20 of 48

Sort: Relevancy | Date

ENBALV: Edoxaban Matches Warfarin After Bioprosthetic Valve Surgery

News Conference News AHA 2024

ENBALV: Edoxaban Matches Warfarin After Bioprosthetic Valve Surgery

Yael L. Maxwell

November 17, 2024

FRAIL-AF: Warfarin Beats NOACs in Frail Elderly With AF

News Conference News ESC 2023

FRAIL-AF: Warfarin Beats NOACs in Frail Elderly With AF

August 28, 2023

CV Care Around Noncardiac Surgery: New ESC Guidelines

News Conference News ESC 2022

CV Care Around Noncardiac Surgery: New ESC Guidelines

Michael O'Riordan

September 07, 2022

Managing AF Patients Undergoing PCI—Some Lingering Questions

News Conference News ACC 2022

Managing AF Patients Undergoing PCI—Some Lingering Questions

Michael O'Riordan

April 12, 2022

Bentracimab Rapidly, Safely Reverses Ticagrelor in Early REVERSE-IT Data

News Conference News AHA 2021

Bentracimab Rapidly, Safely Reverses Ticagrelor in Early REVERSE-IT Data

Yael L. Maxwell

November 15, 2021

2021 ESC/EACTS Valve Guidelines Unveil TAVI/SAVR Age Cutoffs and Earlier Care

News Conference News ESC 2021

2021 ESC/EACTS Valve Guidelines Unveil TAVI/SAVR Age Cutoffs and Earlier Care

August 31, 2021

ENVISAGE-TAVI AF: Edoxaban Disappoints in TAVI Setting

News Conference News ESC 2021

ENVISAGE-TAVI AF: Edoxaban Disappoints in TAVI Setting

August 28, 2021

EHRA Updates Its Popular ‘Practical’ NOAC Guide

News Conference News EHRA 2021

EHRA Updates Its Popular ‘Practical’ NOAC Guide

April 29, 2021

New European NSTE ACS Guidelines Embrace hs-Troponin, CTA, NOAC Trials

News Conference News ESC 2020

New European NSTE ACS Guidelines Embrace hs-Troponin, CTA, NOAC Trials

September 03, 2020

Updated ESC A-fib Guidance Proposes New Path for Diagnosis, Classification, and Care

News Conference News ESC 2020

Updated ESC A-fib Guidance Proposes New Path for Diagnosis, Classification, and Care

August 30, 2020

Some A-fib Patients May Need a Bit More Aspirin After PCI: AUGUSTUS

News Conference News AHA 2019

Some A-fib Patients May Need a Bit More Aspirin After PCI: AUGUSTUS

November 20, 2019

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

News Conference News TCT 2019

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

September 26, 2019

GARFIELD-AF Analysis Digs Into Impact of Bleeding in Newly Diagnosed A-fib

News Conference News ESC 2019

GARFIELD-AF Analysis Digs Into Impact of Bleeding in Newly Diagnosed A-fib

September 12, 2019

LAA Occluders, NOACs Provide Similar Outcomes in High-risk A-fib Patients: PRAGUE-17

News Conference News ESC 2019

LAA Occluders, NOACs Provide Similar Outcomes in High-risk A-fib Patients: PRAGUE-17

September 10, 2019

For A-fib/PCI Combo, Edoxaban Matches VKA but Not Superior: ENTRUST-AF PCI

News Conference News ESC 2019

For A-fib/PCI Combo, Edoxaban Matches VKA but Not Superior: ENTRUST-AF PCI

September 03, 2019

Even in the DOAC Era, Women Less Likely Than Men to Receive Anticoagulation for A-fib

News Conference News HRS 2019

Even in the DOAC Era, Women Less Likely Than Men to Receive Anticoagulation for A-fib

May 17, 2019

Thromboembolic Risks High in Patients With A-fib, Valvular Disease

News Conference News EHRA 2019

Thromboembolic Risks High in Patients With A-fib, Valvular Disease

March 25, 2019

Edoxaban Joins Other NOACs as Option During Catheter Ablation for A-fib

News Conference News EHRA 2019

Edoxaban Joins Other NOACs as Option During Catheter Ablation for A-fib

March 21, 2019

Survey Says . . . Patients Like NOACs Better Than Warfarin

News Conference News EHRA 2019

Survey Says . . . Patients Like NOACs Better Than Warfarin

March 17, 2019

New ESC/EACTS Revascularization Guidelines Make Room for Radial First, STICH, and DES for All

News Conference News ESC 2018

New ESC/EACTS Revascularization Guidelines Make Room for Radial First, STICH, and DES for All

Michael O'Riordan

August 29, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.